Mektovi & Product use in unapproved indication

9.5%

of users reported Product use in unapproved indication

51.4%

also reported Death

55.3%

are women

Death

51.4%

Severe reaction

32.4%

Hospitalization

16.2%

Mektovi: general information

20 - 29 years

0.5%

30 - 39 years

3.6%

40 - 49 years

10.3%

50 - 59 years

22.3%

60 - 69 years

29.2%

70 - 79 years

26.2%

80 - 89 years

8.0%